These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 16296784)

  • 1. Antibody-cytotoxic agent conjugates for cancer therapy.
    Chen J; Jaracz S; Zhao X; Chen S; Ojima I
    Expert Opin Drug Deliv; 2005 Sep; 2(5):873-90. PubMed ID: 16296784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.
    Ojima I
    Acc Chem Res; 2008 Jan; 41(1):108-19. PubMed ID: 17663526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
    Doronina SO; Toki BE; Torgov MY; Mendelsohn BA; Cerveny CG; Chace DF; DeBlanc RL; Gearing RP; Bovee TD; Siegall CB; Francisco JA; Wahl AF; Meyer DL; Senter PD
    Nat Biotechnol; 2003 Jul; 21(7):778-84. PubMed ID: 12778055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technology insight: cytotoxic drug immunoconjugates for cancer therapy.
    Ricart AD; Tolcher AW
    Nat Clin Pract Oncol; 2007 Apr; 4(4):245-55. PubMed ID: 17392715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in tumor-targeting anticancer drug conjugates.
    Jaracz S; Chen J; Kuznetsova LV; Ojima I
    Bioorg Med Chem; 2005 Sep; 13(17):5043-54. PubMed ID: 15955702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-conjugated monoclonal antibodies for the treatment of cancer.
    Lambert JM
    Curr Opin Pharmacol; 2005 Oct; 5(5):543-9. PubMed ID: 16087399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody conjugate therapeutics: challenges and potential.
    Teicher BA; Chari RV
    Clin Cancer Res; 2011 Oct; 17(20):6389-97. PubMed ID: 22003066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo antitumor activity of immunoconjugates prepared by linking 5-fluorouridine to antiadenocarcinoma monoclonal antibody.
    Brusa P; Dosio F; Coppo S; Pacchioni D; Arpicco S; Crosasso P; Cattel L
    Farmaco; 1997 Feb; 52(2):71-81. PubMed ID: 9181686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins.
    Shapira S; Lisiansky V; Arber N; Kraus S
    Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S67-77. PubMed ID: 20374033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Targeting of antitumor drugs with monoclonal antibodies].
    Monneret C; Florent JC
    Bull Cancer; 2000 Nov; 87(11):829-38. PubMed ID: 11125291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunoconjugates, drug-armed antibodies to fight against cancer].
    Haeuw JF; Caussanel V; Beck A
    Med Sci (Paris); 2009 Dec; 25(12):1046-52. PubMed ID: 20035677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in the development and manufacturing of antibody-drug conjugates.
    Ducry L
    Methods Mol Biol; 2012; 899():489-97. PubMed ID: 22735971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-monoclonal antibody conjugates for cancer therapy: potentials and limitations.
    Pimm MV
    Crit Rev Ther Drug Carrier Syst; 1988; 5(3):189-227. PubMed ID: 3060267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody conjugates and therapeutic strategies.
    McCarron PA; Olwill SA; Marouf WM; Buick RJ; Walker B; Scott CJ
    Mol Interv; 2005 Dec; 5(6):368-80. PubMed ID: 16394252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of tumor necrosis factor on the antitumor efficacy and toxicity of aminopterin-monoclonal antibody conjugates: parameters for optimization of therapy.
    Russell SM; Krauer KG; McKenzie IF; Pietersz GA
    Cancer Res; 1990 Sep; 50(18):6028-33. PubMed ID: 2393867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-targeted drugs for the therapy of cancer.
    Pietersz GA; Krauer K
    J Drug Target; 1994; 2(3):183-215. PubMed ID: 7812691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
    Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
    Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours.
    Kelly RK; Olson DL; Sun Y; Wen D; Wortham KA; Antognetti G; Cheung AE; Orozco OE; Yang L; Bailly V; Sanicola M
    Eur J Cancer; 2011 Jul; 47(11):1736-46. PubMed ID: 21458984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts.
    Mazor Y; Noy R; Wels WS; Benhar I
    Cancer Lett; 2007 Nov; 257(1):124-35. PubMed ID: 17698286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.